Serum Markers of Bone Turnover and Angiogenesis in Patients with Bisphosphonate-Related Osteonecrosis of the Jaw after Discontinuation of Long-Term Intravenous Bisphosphonate Therapy

Vivek Thumbigere-Math, Bryan S. Michalowicz, Pamela Hughes, David L. Basi, Michaela L. Tsai, Karen K. Swenson, Laura Rockwell, Rajaram Gopalakrishnan

Research output: Contribution to journalArticle

13 Scopus citations


Purpose To analyze serum markers of bone turnover, angiogenesis, endocrine function, and inflammation in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) who discontinued long-term intravenous bisphosphonate (BP) therapy. Patients and Methods Serum samples were obtained from 25 BRONJ patients who had discontinued long-term intravenous BP therapy for an average of 11.4 ± 8.7 months and 48 non-BRONJ controls who continued receiving intravenous BP therapy. Samples were analyzed for total alkaline phosphatase, bone-specific alkaline phosphatase, osteocalcin, C-telopeptide, vascular endothelial growth factor, triiodothyronine, thyroxine, thyroid-stimulating hormone, 25-hydroxyvitamin D, and C-reactive protein. Results The mean number of BP infusions was significantly higher in BRONJ patients compared with controls (38.4 ± 26.3 infusions vs 18.8 ± 7.2 infusions, P 10 vascular endothelial growth factor (2.9 ± 0.4 pg/mL vs 2.4 ± 0.4 pg/mL, P

Original languageEnglish (US)
Pages (from-to)738-746
Number of pages9
JournalJournal of Oral and Maxillofacial Surgery
Issue number4
StatePublished - Apr 1 2016
Externally publishedYes


ASJC Scopus subject areas

  • Oral Surgery
  • Otorhinolaryngology
  • Surgery

Cite this